SEARCH

SEARCH BY CITATION

References

  • 1
    Cook AF, Holman MJ, Kramer MJ, Trown PW. Fluorinated pyrimidine nucleosides: III. Synthesis and antitumor activity of a series of 5′-deoxy-5-fluoropyrimidine nucleosides. J Med Chem 1979; 22: 13305.
  • 2
    Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, Maruyama HB. Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 1980; 71: 11223.
  • 3
    Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharma Bull 1983; 31: 1758.
  • 4
    Uehara N, Baba H, Nitta K, Kunimoto T, Takeuchi M, Sasaki T, et al. The therapeutic effects of orally administered 5′-deoxy-5-fluorouridine, 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil on experimental murine tumors. Gann 1985; 76: 103441.
  • 5
    Bollag W, Hartmann HR. Tumor inhibitory effects of a new fluorouracil derivative: 5′-deoxy-5-fluorouridine. Eur J Cancer 1980; 16: 42732.
  • 6
    Ohta Y, Sueki K, Kitta K, Takemoto K, Ishitsuka H, Yagi Y. Comparative studies on the immunosuppressive effect among 5′-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil. Gann 1980; 71: 1906.
  • 7
    Armstrong RD, Codman E. 5′-deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow. Cancer Res 1983; 43: 25258.
  • 8
    Wakui A. Phase II trial of 5′-deoxy-5-fluorouridine in the treatment of gastric cancer: a multicenter cooperative study. J Int Med Res 1988; 16 (Suppl 2): 17B8B.
  • 9
    Niitani H, Kimura K, Saito T, Nakao I, Abe O, Urushizaki I, et al. Phase II study of 5′-deoxy-5-fluorouridine (5′-DFUR) on patients with malignant cancer: multi-institutional cooperative study. Gan To Kagaku Rhoyo 1985; 12: 204451 (in Japanese).
  • 10
    Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr. Cis-dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; 63: 145973.
  • 11
    Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 89235.
  • 12
    Ohtsu A, Yoshida S, Saito D, Shimada Y, Miyamoto K, Fujii T, et al. An early Phase II study of 5-fluorouracil combined with cis-platinum as a second line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 1991; 21: 1204.
  • 13
    Kurihara M, Niitani H. A comparative, randomized and controlled study of the efficacy and safety of 5′-deoxy-5-fluorouridine administered daily or intermittently. J Int Med Res 1988; 16 (Suppl 2): 30B1B.
  • 14
    Pratesi G, Gianni L, Manzotti C, Zunino F. Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol 1988; 21: 23740.
  • 15
    Japanese Research Society for Gastric Cancer. General rules for gastric cancer study. 11th ed. Tokyo: Kanehara, 1985: 10135 (in Japanese).
  • 16
    Kurihara M, Izumi T, Ito T. Evaluation of the effect of chemotherapy in gastric cancer patients with an intact primary tumor according to the criteria of the Japanese Research Society for Gastric Cancer. J Jpn Soc Cancer Ther 1991; 26: 64454.
  • 17
    Macdonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS. 5-fluorouracil, Adriamycin, and mitomycin-c (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 1979; 44: 427.
  • 18
    The Gastrointestinal Tumor Study Group. Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 1984; 53: 137.
  • 19
    Lacave AJ, Izarzugaza I, Aparicio LMA, Pereda MV, Marco JMG, Buesa JM. Phase II clinical trial of cis-dichlorodiammine-platinum in gastric cancer. Am J Clin Oncol 1983; 6: 358.
  • 20
    Lacave AJ, Wils J, Diaz-Rubio E, Clavel M, Planting A, Bleiberg H, et al. Cis-platinum as second-line chemotherapy in advanced gastric adenocarcinoma: a Phase II study of the EORTC gastrointestinal tract cancer cooperative group. Eur J Cancer Clin Oncol 1985; 21: 13214.
  • 21
    Leichman L, McDonald B, Dindogru FA, Samson M, Vaitkevicius VK. Cisplatin: an active drug in the treatment of disseminated gastric cancer. Cancer 1984; 53: 1822.
  • 22
    Vogl SE, Engstrom PF. Cisplatin, doxorubicin, and 5-FU in combination for advanced gastric cancer. Cancer Treat Rep 1984; 68: 12735.
  • 23
    Moertel CG, Rubin J, O'Connell MJ, Schutt AJ, Wieand HS. A Phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 1986; 4: 10537.
  • 24
    Delfino C, Caccia G, Alasino C, Fein L, Galvez C, Muro H, et al. 5-Fluorouracil(F) + epirubicin(E) + cisplatin(C) in patients (PTS) with advanced gastric cancer (AGC) [abstract]. Proc Am Soc Clin Oncol 1990; 9: 123.
  • 25
    Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989; 7: 13107.
  • 26
    Preusser P, Wilke H, Achterrath W, Neuhaus B, Balleisen L, Meyer J, et al. Advanced inoperable stomach cancer: a pilot study with the combination etoposide, adriamycin and cisplatin. Anticancer Res 1986; 6: 11956.
  • 27
    Taguchi T. Combination chemotherapy with etoposide (E), Adriamycin (A) and cisplatin (P) (EAP) for advanced gastric cancer [abstract]. Proc Am Soc Clin Oncol 1989; 8: 108.
  • 28
    Lerner A, Steele GD, Mayer RJ. Etoposide, doxorubicin, cisplatin (EAP) chemotherapy for advanced gastric adenocarcinoma: results of a Phase II trial [abstract]. Proc Am Soc Clin Oncol 1990; 9: 103.
  • 29
    Suzuki S, Hongu Y, Fukazawa H, Ichihara S, Simizu H. Tissue distribution of 5′-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats. Gann 1980; 71: 23845.
  • 30
    Tanaka Y, Eda H, Fujimoto K, Tanaka T, Ishikawa T, Ishitsuka H. Anticachectic activity of 5′-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res 1990; 50: 452832.